Budesonide inhalation - Vectura

Drug Profile

Budesonide inhalation - Vectura

Alternative Names: AKITA inhaled budesonide suspension - Activaero GmBH; Favolir; Flavorestin™; Scipe; VR 475; VR 647

Latest Information Update: 29 Nov 2016

Price : $50

At a glance

  • Originator Activaero GmbH
  • Developer Activaero GmbH; Vectura
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma

Most Recent Events

  • 23 Nov 2016 Vectura plans a phase I trial for paediatric Asthma
  • 15 Mar 2016 Biomarkers information updated
  • 19 Feb 2016 No recent reports on development identified - Phase-II for Asthma (In adults) in Ukraine (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top